<DOC>
	<DOCNO>NCT02353819</DOCNO>
	<brief_summary>Since high risk prostate cancer require high radiation , study do determine maximum tolerate dose radiation prostate pelvic region . Also determine feasibility safety treatment fraction use cone-beam Computed Tomography ( CT ) information high speed Graphics Processing Unit base computation treatment plan system . We also plan determine safety treatment prostate . Health-related quality life measure part current clinical practice . - Determine maximum tolerate dose ( MTD ) safely escalate dose pelvic nodal use 90 day acute toxicity endpoint - Determine feasibility safety adaptive real time re-planning pelvic nodal region treatment fraction use cone-beam CT ( CBCT ) information high speed GPU base computation treatment plan system - Determine safety tolerability 9.5 Gy per fraction five fraction ( 47.5 Gy total dose ) prostate - To follow tumor relate outcome ( i.e . PSA control , progression-free survival ( PFS ) , distant metastasis ( DM ) free survival , overall survival ( OS ) - Health-related quality life ( HRQOL ) measure part current clinical practice Patients dose cohort treat single group dose escalation . There two level dose escalation—to prostate lesion pelvic lymph node region . Prostate/SV PTV treat fix dose 9.5 Gy per fraction 5 fraction ( 47.5 Gy ) base previous phase I/II study experience . The start dose dose escalation pelvic region PTV 4.5 Gy per fraction 5 fraction ( total dose= 22.5 Gy ) . Subsequent cohort patient receive additional 0.5 Gy per treatment ( total 2.5 Gy per escalation ) . The start dose MRI-visible prostatic lesion 10 Gy subsequent cohort receive additional 0.5Gy per treatment ( total 2.5Gy per escalation ) .</brief_summary>
	<brief_title>Stereotactic Ablative Radiotherapy ( SABR ) Pelvis Prostate Targets For High Risk Prostate Cancer</brief_title>
	<detailed_description>Patients accrue alternate dose level . The two distinct area dose escalation ( pelvic lymph node prostate lesion ) take place one time . Minimum wait period assign dose cohort observe toxicity . The phase I portion study complete dose limit toxicity reach sufficiently high dose level ( i.e.,5.5 Gy per fraction total 27.5 Gy pelvic lymph node region 11Gy per fraction total 55Gy prostate lesion ) , attain consider therapy likely efficacious . All patient treat total 24 month androgen suppression therapy ( ADT ) . Radiation therapy start 8-12 week initiation ADT . No . Patients cohort : 7-15 Cohort 1 : 9.5 Gy per fraction prostate/SV , 10 Gy per fraction prostate lesion , 4.5Gy per fraction pelvic lymph node region 5 fraction total 47.5 / 50 / 22.5 Gy Prostate+SV /Prostate lesions/Nodes Cohort 2 : 9.5 Gy per fraction prostate/SV , 10 Gy per fraction prostate lesion , 5Gy per fraction pelvic lymph node region 5 fraction total 47.5 / 50 / 25 Gy Prostate+SV /Prostate lesions/Nodes Cohort 3 : 9.5 Gy per fraction prostate/SV , 10.5 Gy per fraction prostate lesion , 5Gy per fraction pelvic lymph node region 5 fraction total 47.5 / 52.5 / 25 Gy Prostate+SV /Prostate lesions/Nodes Cohort 4 : 9.5 Gy per fraction prostate/SV , 10.5 Gy per fraction prostate lesion , 5.5 Gy per fraction pelvic lymph node region 5 fraction total 47.5 / 52.5 / 27.5 Gy Prostate+SV /Prostate lesions/Nodes Cohort 5 : 9.5 Gy per fraction prostate/SV , 11 Gy per fraction prostate lesion , 5.5 Gy per fraction pelvic lymph node region 5 fraction total 47.5 / 55 / 27.5 Gy Prostate+SV /Prostate lesions/Nodes</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Signed study specific inform consent form . PSA ≥20 OR Gleason score ≥ 8 OR Appropriate stag study identify AJCC stage cT3+ ( MR stage T3a without high risk factor permit investigator discretion ) . No direct evidence regional distant metastasis appropriate stag study indicate clinically . Clinically negative lymph node establish image ( abdominal pelvic CT abdominal pelvic MRI ) , nodal sampling , dissection within 90 day prior registration . Patients lymph node equivocal questionable image eligible node &lt; 2.0 cm short axis . No distant metastasis ( M0 ) bone scan within 90 day prior registration . Histologic confirmation cancer biopsy Adenocarcinoma prostate Age ≥18 Zubrod Performance Status 02 AUA score must ≤20 ( alpha blocker allow ) CT Ultrasoundbased volume estimation prostate gland ≤80 gram ( repeat ultrasound measurement hormone downsizing allow ) Agreement use effective contraceptive method condom/diaphragm spermicidal foam , intrauterine device , prescription birth control pill . Equivocal bone scan finding allow plain film negative metastasis . Deemed eligible Complete Androgen Blockade ( CAB ) hormone therapy treat physician , include baseline liver function evaluation . For patient eligible antitestosterone therapy , hormone therapy LHRH agonist alone permit case case basis study P.I . Use previous hormonal therapy 9 month allow treatment prostate cancer well prostate volume reduction . MRI Pelvis/Prostate feasible stag plan Clinically eligible rectal spacer insertion ( e.g . Duraseal , SpaceOAR , equivalent product ) per physician evaluation Positive lymph node metastatic disease prostate cancer image study ( CT MRI ) , unless biopsy proven negative . Evidence metastatic disease imaging study Prior invasive malignancy unless disease free minimum 3 year ( oral cavity , nonmelanomatous skin cancer permissible ) Previous pelvic radiotherapy Previous surgery chemotherapy prostate cancer Previous transuretheral resection prostate ( TURP ) cryotherapy prostate Previous androgen depravation therapy give 9 month prior therapy Concomitant antineoplastic therapy ( include surgery , cryotherapy , conventionally fractionate radiotherapy , chemotherapy ) protocol . History Crohn 's Disease Ulcerative Colitis . Not actively immunosuppressive medication . Previous significant obstructive symptom ; AUA score must ≤20 ( alpha blocker allow ) Significant psychiatric illness Men reproductive potential may participate unless agree use effective contraceptive method . Ultrasound CT estimate prostate volume &gt; 80 gram ( hormone downsizing allow ) . Severe , active comorbidity No nodal disease No known allergy spacer material : Polyethylene glycol ( PEG ) hydrogel</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>